Axsome Therapeutics Settles SUNOSI® (solriamfetol) Patent Litigation with Alkem Laboratories Ltd.

Rhea-AI Summary

Axsome Therapeutics (NASDAQ: AXSM) announced a settlement with Alkem Laboratories resolving patent litigation over SUNOSI (solriamfetol). Under the agreement, Alkem may market a generic SUNOSI on or after March 1, 2040 (or September 1, 2040 if pediatric exclusivity is granted), subject to FDA approval and customary conditions.

The companies will submit the settlement to the U.S. Federal Trade Commission and Department of Justice for review. Separate SUNOSI litigation against another party remains pending in New Jersey.

Positive

• Clear generic-entry dates: March 1, 2040 or September 1, 2040
• Settlement reduces immediate litigation uncertainty for SUNOSI
• License terms subject to FDA approval, aligning with regulatory norms

Negative

• Potential generic competition beginning in 2040 could cap long-term sales
• Settlement requires FTC and DOJ review, which may delay finality
• Other SUNOSI litigation remains pending in U.S. District Court

News Market Reaction – AXSM

+1.15%

+1.15% Session close to close

In the Feb 17 session, AXSM gained 1.15%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement resolves SUNOSI patent litigation by licensing Alkem to launch a generic product o...

Analysis

This announcement resolves SUNOSI patent litigation by licensing Alkem to launch a generic product only from 2040 onward, depending on pediatric exclusivity. It effectively preserves Axsome’s U.S. market position for SUNOSI for many years, while similar litigation with another party remains pending. Investors may weigh this long-dated protection against the company’s broader revenue and late-stage CNS pipeline updates and ongoing insider trading activity when assessing overall risk-reward.

Key Figures

Generic entry with pediatric exclusivity: On or after September 1, 2040 Generic entry without pediatric exclusivity: On or after March 1, 2040

2 metrics

Generic entry with pediatric exclusivity On or after September 1, 2040 License start date for Alkem generic SUNOSI, if pediatric exclusivity granted

Generic entry without pediatric exclusivity On or after March 1, 2040 License start date for Alkem generic SUNOSI, if no pediatric exclusivity granted

Historical Context

5 past events · Latest: Jan 27 (Neutral)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Jan 27	Earnings call date	Neutral	+1.9%	Announcement of Q4 and full-year 2025 earnings release and conference call.
Jan 15	Phase 3 initiation	Positive	-1.6%	First patient dosed in FORWARD Phase 3 trial of AXS-14 for fibromyalgia.
Jan 12	Prelim revenues	Positive	+4.4%	Preliminary Q4 and 2025 net product revenue with strong growth in key brands.
Dec 31	Priority Review	Positive	+22.8%	FDA acceptance and Priority Review of sNDA for AXS-05 in Alzheimer’s agitation.
Dec 31	Pre-NDA feedback	Positive	+22.8%	FDA pre-NDA meeting minutes supporting NDA submission for AXS-12 in narcolepsy.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

AXSM has generally reacted positively to major clinical and revenue updates, with one divergence on a Phase 3 initiation.

Recent Company History

Recent AXSM news has focused on revenue growth and late-stage CNS pipeline progress. Preliminary Q4 and full-year 2025 net product revenue showed strong growth, prompting a 4.39% gain. Multiple late-2025 clinical updates, including FDA Priority Review for AXS-05 with an April 30, 2026 PDUFA date and NDA-supportive feedback for AXS-12, each coincided with 22.75% moves. A Phase 3 initiation for AXS-14 saw a modest -1.62% reaction. Today’s SUNOSI patent settlement adds to a pattern of strengthening the commercial portfolio and exclusivity.

Key Terms

abbreviated new drug application, u.s. food and drug administration, pediatric exclusivity, u.s. federal trade commission, +1 more

5 terms

abbreviated new drug application regulatory

"resulted from submission by Alkem of an Abbreviated New Drug Application to the U.S."

An abbreviated new drug application is a regulatory submission used to gain approval to market a generic version of an already approved prescription medicine by showing it is equivalent in effect and safety to the original product, without repeating full clinical trials. For investors, an approval signals a lower-cost competitor entering the market that can quickly capture sales from the branded drug, similar to a generic knock‑off replacing a name‑brand item on store shelves.

u.s. food and drug administration regulatory

"Abbreviated New Drug Application to the U.S. Food and Drug Administration seeking approval"

The U.S. Food and Drug Administration is the federal agency that evaluates and enforces safety, effectiveness and labeling standards for medicines, medical devices, vaccines, food and related products before they reach consumers. For investors it matters because FDA approvals, warnings or recalls determine whether a product can be sold, how quickly it reaches the market and how costly compliance will be—changes that directly affect a company’s revenue, costs and stock value.

pediatric exclusivity regulatory

"beginning on or after September 1, 2040, if pediatric exclusivity is granted for SUNOSI"

Pediatric exclusivity is a regulatory reward that gives a drug maker extra protected selling time—typically a six‑month extension—if the company conducts studies showing the medicine is safe and effective for children. For investors, it matters because that extra time is like a temporary shield that delays generic competition and can materially extend revenue from a product, affecting a drug’s cash flow, valuation and investment returns.

u.s. federal trade commission regulatory

"Axsome and Alkem will submit the settlement agreement to the U.S. Federal Trade Commission"

The U.S. Federal Trade Commission (FTC) is a federal agency that polices fair competition and protects consumers by stopping deceptive advertising, unfair business practices, and anticompetitive mergers. Think of it as a referee for the marketplace: its investigations, fines, or orders can change a company’s legal risk, cost structure, or ability to grow through acquisitions, so investors watch it closely for signals that could affect a company’s future profits and valuation.

u.s. department of justice regulatory

"and the U.S. Department of Justice for review."

The U.S. Department of Justice is the federal agency that enforces national laws, prosecutes crimes, and brings civil lawsuits on behalf of the government — think of it as the country’s legal referee and law office. For investors, its actions matter because investigations, antitrust suits, criminal charges, or enforcement actions can lead to fines, operational limits, or reputational damage that directly affect a company’s finances and stock value.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

NEW YORK, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM) (Axsome), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced that it has entered into a settlement agreement with Alkem Laboratories Ltd. (Alkem) resolving patent litigation related to Axsome’s product SUNOSI^® (solriamfetol). The litigation, which is pending in the United States District Court for the District of New Jersey, resulted from submission by Alkem of an Abbreviated New Drug Application to the U.S. Food and Drug Administration seeking approval to market a generic version of SUNOSI in the United States. Under the terms of the settlement agreement, Axsome will grant Alkem a license to sell its generic version of SUNOSI beginning on or after September 1, 2040, if pediatric exclusivity is granted for SUNOSI, or on or after March 1, 2040, if no pediatric exclusivity is granted, subject to FDA approval and conditions and exceptions customary for agreements of this type.

As required by law, Axsome and Alkem will submit the settlement agreement to the U.S. Federal Trade Commission and the U.S. Department of Justice for review. Similar patent litigation brought by Axsome against another party related to SUNOSI remains pending in the U.S. District Court for the District of New Jersey.

About Axsome Therapeutics

Axsome Therapeutics is a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) conditions. We deliver scientific breakthroughs by identifying critical gaps in care and develop differentiated products with a focus on novel mechanisms of action that enable meaningful advancements in patient outcomes. Our industry-leading neuroscience portfolio includes FDA-approved treatments for major depressive disorder, excessive daytime sleepiness associated with narcolepsy and obstructive sleep apnea, and migraine, and multiple late-stage development programs addressing a broad range of serious neurological and psychiatric conditions that impact over 150 million people in the United States. Together, we are on a mission to solve some of the brain’s biggest problems so patients and their loved ones can flourish. For more information, please visit us at www.axsome.com and follow us on LinkedIn and X.

Forward Looking Statements

Certain matters discussed in this press release are “forward-looking statements”. The Company may, in some cases, use terms such as “predicts,” “believes,” “potential,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. In particular, the Company’s statements regarding trends and potential future results are examples of such forward-looking statements. The forward-looking statements include risks and uncertainties, including, but not limited to, the commercial success of the Company’s SUNOSI^®, AUVELITY^®, and SYMBRAVO^® products and the success of the Company’s efforts to obtain any additional indication(s) with respect to solriamfetol and/or AXS-05; the Company’s ability to maintain and expand payer coverage; the success, timing and cost of the Company’s ongoing clinical trials and anticipated clinical trials for the Company’s current product candidates, including statements regarding the timing of initiation, pace of enrollment and completion of the trials (including the Company’s ability to fully fund the Company’s disclosed clinical trials, which assumes no material changes to the Company’s currently projected revenues or expenses), futility analyses and receipt of interim results, which are not necessarily indicative of the final results of the Company’s ongoing clinical trials, and/or data readouts, and the number or type of studies or nature of results necessary to support the filing of a new drug application (“NDA”) for any of the Company’s current product candidates; the Company’s ability to fund additional clinical trials to continue the advancement of the Company’s product candidates; the timing of and the Company’s ability to obtain and maintain U.S. Food and Drug Administration (“FDA”) or other regulatory authority approval of, or other action with respect to, the Company’s product candidates, including statements regarding the timing of any NDA submission; the Company’s ability to successfully defend its intellectual property or obtain the necessary licenses at a cost acceptable to the Company, if at all; the Company’s ability to successfully resolve any intellectual property litigation, and even if such disputes are settled, whether the applicable federal agencies will approve of such settlements; the successful implementation of the Company’s research and development programs and collaborations; the success of the Company’s license agreements; the acceptance by the market of the Company’s products and product candidates, if approved; the Company’s anticipated capital requirements, including the amount of capital required for the commercialization of SUNOSI, AUVELITY, and SYMBRAVO and for the Company’s commercial launch of its other product candidates, if approved, and the potential impact on the Company’s anticipated cash runway; the Company’s ability to convert sales to recognized revenue and maintain a favorable gross to net sales; unforeseen circumstances or other disruptions to normal business operations arising from or related to domestic political climate, geo-political conflicts or a global pandemic and other factors, including general economic conditions and regulatory developments, not within the Company’s control. The factors discussed herein could cause actual results and developments to be materially different from those expressed in or implied by such statements. The forward-looking statements are made only as of the date of this press release and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.

Investors:
Ashley Dong
Director, Investor Relations
(929) 687-1614
adong@axsome.com

Media:
Darren Opland
Senior Director, Corporate Communications
(929) 837-1065
dopland@axsome.com

FAQ

When can Alkem market a generic SUNOSI under the Axsome settlement (AXSM)?

Alkem may market a generic SUNOSI on or after March 1, 2040 (or September 1, 2040 with pediatric exclusivity). According to the company, this timing is conditional on FDA approval and customary agreement exceptions.

Does the Axsome settlement require regulatory review for the SUNOSI license?

Yes, the settlement will be submitted to the U.S. Federal Trade Commission and Department of Justice for review. According to the company, these submissions are required by law and could affect timing and implementation.

How does pediatric exclusivity affect SUNOSI generic-entry dates for AXSM?

Pediatric exclusivity would delay generic entry to September 1, 2040 instead of March 1, 2040. According to the company, the later date applies only if pediatric exclusivity is granted for SUNOSI.

Is FDA approval required before Alkem can sell a generic SUNOSI under the AXSM deal?

Yes, FDA approval is required before Alkem may market the generic. According to the company, the license is subject to FDA approval and customary conditions and exceptions.

Does this settlement end all SUNOSI patent litigation involving Axsome (AXSM)?

No, the settlement resolves litigation with Alkem but not all cases; other SUNOSI litigation remains pending in New Jersey. According to the company, at least one related case continues in U.S. District Court.